Ypsomed’s insulin pump has been marketed in Europe since 2016. Available in 21 countries as the mylife YpsoPump, this pump stands out for its small size and its unique, icon-based touch screen. Lilly will commercialize a version of this insulin pump, along with continuous glucose monitoring (CGM) and automated insulin delivery technology, in the United States and Europe. This pump will use pre-filled insulin cartridges for Lilly’s rapid-acting insulins.
“Lilly is committed to delivering solutions that meet the needs of the diabetes community and providing more options to help them manage their diabetes,” said Marie Schiller, vice president of product development for Connected Care and Insulins at Lilly. “People who use insulin, along with their healthcare providers, need simple, effective tools that lead to improved outcomes, and Ypsomed is developing an automated insulin delivery system with several exciting features that can help meet that need.”
Ypsomed plans to submit a version of the mylife YpsoPump for clearance to the U.S. Food and Drug Administration for use in automated insulin delivery in 2022. If cleared, Lilly will have exclusive rights to commercialize the pump in the U.S.
“We are thrilled to partner with Lilly to bring our insulin pump to the United States and deliver improved outcomes to people with diabetes through connected solutions,” said Simon Michel, CEO of Ypsomed. “Managing diabetes with insulin is already complex enough, so we developed this insulin pump to be easy to learn and easy to operate. Our goal is to support people living with diabetes through app-centric insulin management, CGM data and advanced algorithms. Partnering with Lilly to bring a holistic platform to market is an important next step in this journey that started in 1984 by introducing the world’s first micro insulin pump to the market.”